TransCode shareholders elect directors and approve stock plan increase at 2025 annual meeting

Transcode Therapeutics, Inc.

Elected directors Philippe Calais, Thomas Fitzgerald, Erik Manting, Magda Marquet; each received >84K votes for.
Approved amendment to 2021 stock plan increasing authorized shares by 166,724; 76,322 for, 18,310 against, 1,434 abstained.
Ratified WithumSmith+Brown as auditor for FY2025: 301,629 for, 7,844 against, 2,810 abstain; no broker non-votes.
Adjournment proposal passed but not needed because sufficient votes existed for the stock plan amendment.

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.